Written by The global Alzheimer’s disease biomarkers market is witnessing steady expansion as the prevalence of Alzheimer’s disease and other forms of dementia continues to rise worldwide. Alzheimer’s disease is a progressive and irreversible neurodegenerative disorder that affects memory, cognition, behavior, and functional independence. Biomarkers provide measurable indicators of biological processes associated with disease development and progression and are increasingly being used for early detection, predictive diagnosis, disease monitoring, treatment response assessment, and research. The growing emphasis on identifying Alzheimer’s disease at an early stage is encouraging the development and adoption of biomarkers based on proteins, peptides, genes, imaging characteristics, and other measurable biological signals. Advances in diagnostic technologies, increasing investments in neurological research, and the development of personalized treatment strategies are further supporting market growth. The rising need for accurate and confirmatory diagnostic tools is also encouraging pharmaceutical companies, diagnostic developers, research institutions, and biotechnology companies to expand their biomarker portfolios.
👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=44970
Market Size and Growth
The global Alzheimer’s disease biomarkers industry was valued at US$ 825.2 Mn in 2021 and is anticipated to grow at a CAGR of 7.3% from 2022 to 2031, reaching more than US$ 1.7 Bn by the end of 2031. The expansion of the market is strongly associated with the rapidly aging global population, since advanced age is one of the most significant risk factors for dementia and Alzheimer’s disease. According to the information provided, approximately 47 million people were living with dementia globally in 2020, with the number expected to increase substantially over the coming decades. This demographic shift is creating an urgent need for efficient diagnostic approaches capable of identifying disease-related biological changes before severe cognitive decline occurs. In addition, growing awareness of the importance of early diagnosis, increased clinical research activity, and the development of disease-modifying therapies are expected to create additional demand for reliable biomarkers. The growing use of biomarkers in clinical trials is another important growth factor, as researchers require objective measures to assess disease progression and evaluate therapeutic outcomes.
Market Segmentation
Based on biomarker type, cerebrospinal fluid (CSF) biomarkers accounted for a major share of the global market in 2021. CSF has direct physical contact with the brain and can contain proteins and peptides that reflect neurological changes and Alzheimer’s disease pathology, making it a valuable source for disease assessment. CSF biomarkers can also support prediction of disease progression and outcome assessment in clinical trials evaluating disease-modifying therapies. Their ability to provide information about evolving pathological processes makes them particularly important in research and diagnostic applications. In terms of detection technique, immunoassays are expected to account for a significant share of market growth during the forecast period. Immunoassays are comparatively accessible, cost-effective, and adaptable to biological samples, while established availability across pharmaceutical and diagnostic industries supports their continued use. At the same time, the market is gradually expanding toward innovative approaches, including blood-based biomarkers and digital biomarkers, which could improve accessibility and enable less invasive monitoring in the future.
Regional Analysis
North America held the largest share of approximately 35.0% in 2021 and is expected to maintain a significant position during the forecast period. The region’s leadership is supported by the presence of major market participants, well-established healthcare infrastructure, high levels of research and development expenditure, and increasing research activity focused on neurological diseases. The United States represents the dominant market in North America, supported by extensive clinical research and the presence of companies developing innovative biomarker technologies. Meanwhile, Asia Pacific is projected to be the fastest-growing regional market during the forecast period. The region’s growth is being supported by its large and aging population, increasing incidence of dementia and other neurological disorders, improving healthcare infrastructure, and rising investments in medical research. Increasing awareness of early diagnosis and the expansion of healthcare capabilities across emerging economies are expected to strengthen demand for Alzheimer’s disease biomarker technologies.
Competitive Landscape
The global Alzheimer’s disease biomarkers market is fragmented and includes a broad range of companies operating across diagnostics, life sciences, biotechnology, and research applications. Leading participants are investing significantly in research and development to introduce innovative biomarker solutions, including emerging digital and blood-based biomarker technologies. Product launches, regulatory approvals, portfolio expansion, strategic collaborations, partnerships, and mergers and acquisitions are among the key strategies being adopted to strengthen market presence and expand customer reach. Prominent companies identified in the market include Enzo Life Sciences, Inc., Thermo Fisher Scientific, Inc., AnaSpec, Inc., Merck KGaA, Cell Signaling Technology, Inc., Fujirebio, Imagilys, NanoSomiX, QIAGEN, 23andMe, Inc., Quanterix, C₂N Diagnostics, and Quest Diagnostics. Competition is expected to intensify as companies seek to develop biomarkers that provide greater diagnostic accuracy, improved sensitivity, easier sample collection, and stronger potential for integration into routine clinical practice.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453